Clinical Trial Update: Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1) [Phase 2]

View source ↗

Summary

Phase II study results for pirfenidone in rheumatoid arthritis–associated interstitial lung disease (RA-ILD) have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis Interstitial Lung Disease

Drugs mentioned

• PIRFENIDONE (pirfenidone)

Snippet

Sponsor: Brigham and Women's Hospital | Conditions: Rheumatoid Arthritis Interstitial Lung Disease | Phase 2 | Status: COMPLETED | Results posted: 2022-08-16